At the news
? BEARISHIMPACT 6/10 8-K filed May 29, 2026 at 16:30 ET
Outlook Therapeutics filed an 8-K disclosing a registered direct offering of 8,539,709 shares of common stock to GMS Ventures and Investments, priced under an existing effective shelf registration statement. The offering represents approximately 9.6% dilution relative to the $89M market cap, providing near-term cash but pressuring the stock via share count expansion.
- Registered direct offering of 8,539,709 shares to GMS Ventures and Investments
- Securities purchase agreement dated May 28, 2026
- Offering made under effective S-3 shelf (File No. 333-278340)
- Shares represent ~9.6% of pre-offering shares outstanding based on $89M market cap
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access